Information Provided By: 
Fly News Breaks for February 3, 2020
AIMT
Feb 3, 2020 | 09:02 EDT
JMP Securities analyst Liisa Bayko raised her price on Aimmune to $44 and kept her Outperform rating after the FDA approved its PALFORZIA as the first treatment for peanut allergy last week. The analyst anticipates its commercial launch by March 1st, with pricing of about $10K per year seen as the high end of expectations. Bayko adds that year 1 should see about $50M in PALFORZIA sales, followed by $200M in year 2 and up to $1B over the long term.
News For AIMT From the Last 2 Days
There are no results for your query AIMT
